All Categories
| | 
Home
What is GLP-1
**Introduction to GLP-1 (Glucagon-Like Peptide-1)** GLP-1 (Glucagon-Like Peptide-1) is a naturally occurring incretin hormone that plays a key role in glucose metabolism and appetite regulation. Produced in the gut, GLP-1 enhances insulin secretion, suppresses glucagon release, slows gastric emptying, and promotes satiety—making it a promising therapeutic target for type 2 diabetes and obesity. Synthetic GLP-1 receptor agonists (GLP-1 RAs), such as liraglutide and semaglutide, mimic these effects, helping improve glycemic control and support weight loss. With additional cardiovascular benefits observed in clinical trials, GLP-1-based therapies have become a cornerstone in metabolic disease management. Their dual action on blood sugar and weight makes them a versatile and effective treatment option.
Preparation Process: GLP-1 (glucagon-like peptide-1) is typically prepared via solid-phase peptide synthesis (SPPS). The process begins with attaching the C-terminal amino acid (e.g., glycine) to a resin. Subsequent amino acids are added stepwise using Fmoc or Boc chemistry, with deprotection and coupling cycles. After chain assembly, the peptide is cleaved from the resin using a trifluoroacetic acid (TFA) cocktail, followed by precipitation in cold ether. Purification is performed via reversed-phase HPLC, and the product is lyophilized. Alternatively, recombinant DNA technology can express GLP-1 in E. coli or yeast, followed by extraction, refolding, and purification. Final characterization is done via mass spectrometry and analytical HPLC.
Usage Scenarios: GLP-1 (glucagon-like peptide-1) is a hormone that enhances insulin secretion, suppresses glucagon release, and slows gastric emptying, aiding in blood sugar regulation. It is used to treat type 2 diabetes by improving glycemic control, often through GLP-1 receptor agonists like exenatide and liraglutide. These drugs promote weight loss by increasing satiety and reducing appetite. GLP-1-based therapies also show cardiovascular benefits, lowering the risk of heart disease in diabetic patients. Recent research explores its potential in obesity management and neurodegenerative diseases. The compound’s ability to stimulate insulin only in hyperglycemic states minimizes hypoglycemia risk, making it a safer antidiabetic option.
GLP-1 Basic Info
Safely Info
GLP-1 Price
1. **United States**: $800 - $1,500 per month
2. **China**: $300 - $700 per month
3. **Russia**: $400 - $900 per month
4. **Germany**: $600 - $1,200 per month
5. **India**: $200 - $500 per month
6. **Japan**: $700 - $1,300 per month
7. **Brazil**: $400 - $800 per month
8. **South Korea**: $500 - $1,000 per month
9. **Philippines**: $300 - $600 per month
10. **United Kingdom**: $600 - $1,100 per month
11. **France**: $600 - $1,200 per month
12. **Mexico**: $400 - $800 per month
13. **Canada**: $700 - $1,300 per month
14. **South Africa**: $300 - $700 per month
15. **Egypt**: $200 - $500 per month
16. **Turkey**: $300 - $700 per month
17. **Thailand**: $250 - $600 per month
18. **Indonesia**: $200 - $500 per month
*Note: These are approximate ranges and may vary significantly based on factors like dosage, brand, and local healthcare policies. If no specific data is available for a country, the range is based on regional trends.*
GLP-1 Products
Total12
Products
GLP-1 Suppliers
Hot Recommendation
